|
Overall trial success probability across all clinical phases
|
15.81%
|
13.37%
|
|
Cost per successful new drug
|
2190 million USD
|
2390 million USD
|
|
Cost savings per successful new drug compared to DiMasi et al. (2016)
|
370 million USD (−14.4%)
|
170 million USD (−6.6%)
|
|
Global cost reductions
|
14.4 bn USD
|
6.6 bn USD
|
|
Induced additional global R&D investments [lower; upper bound]
|
4.22 bn USD [2.12 bn;8.44 bn]
|
1.94 bn USD [0.970 bn; 3.87 bn]
|
|
Generated gain in life-years (in US) [lower; upper bound]
|
3.46 mill [1.74 mill; 6.93 mill]
|
1.58 mill [1.30 mill;3.17 mill]
|
